Hong Kong · Delayed Price · Currency is HKD Jacobio Pharmaceuticals Group Company Description
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People’s Republic of China.
The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic malignancies; JAB-BX102, a humanized monoclonal antibody against CD73, which is in a Phase I/IIa trial; JAB-2485, a highly selective Aurora Kinase A (AURKA) inhibitor that is in a Phase I/IIa trial for solid tumors; JAB-23E73, an oral small-molecule pan-KRAS inhibitor that is in a Phase I trial for KRAS-mutant PDAC, CRC, NSCLC, and solid tumors; and JAB-30355, a bioavailable small molecule p53 reactivator that is in a Phase I trial for the treatment of patients with locally advanced or metastatic solid tumors.
It is also developing IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications.
The company has a collaboration agreement with AstraZeneca AB to develop and commercialize JAB-23E73.
Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China.
| Country | Cayman Islands |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 67 |
| CEO | Yinxiang Wang |
Contact Details
Address: Building 8 Beijing China | |
| Phone | 86 10 5631 5043 |
| Website | jacobiopharma.com |
Stock Details
| Ticker Symbol | 1167 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG4987A1094 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrea Wang-Gillam M.D., Ph.D. | Co-Chief Executive Officer, Executive Vice President, Chief Medical Officer and Global Head of Research & Development |
| Dr. Yinxiang Wang | Founder, Co-Chief Executive Officer and Executive Chairman |
| Xiaojie Wang | Executive Director and President of Administration |
| Yunyan Hu | Executive Vice President and Executive Director |
| Tao Yang | Vice President of Human Resources |
| Yanping Wang | Executive Vice President of Non-Clinical Research & Development |
| Dr. Haijun Wang | Senior Vice President of Information and Data Management |
| Yuli Ding | Executive Vice President of Clinical Development |
| Qing Xue | Joint Company Secretary |
| Ming Fai Chung CPA | Joint Company Secretary |